An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Fexofenadine Cmax (alone and in combination with osimertinib)
研究概览
简要总结
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent.
Part A will assess the effect of osimertinib on the pharmacokinetic (PK) parameters of fexofenadine, following single and multiple oral dosing of osimertinib in a fasted state.
Continuous Access will allow patients further access to osimertinib after the PK phase (Part A). All patients from Part A who completed treatment may continue to receive osimertinib 80 mg once daily until: they are no longer deriving clinical benefit; or any other reason
详细描述
This is a Phase I, open-label, non-randomised, two-part study in patients with EGFRm+ NSCLC who have progressed on an EGFR-TKI.
The PK phase will assess the effect of osimertinib on the PK parameters of fexofenadine following both single and multiple oral dosing of osimertinib. Continued access will provide patients with further access to osimertinib after the PK phase.
The study will be conducted at approximately 10 sites across Asia and Western Europe, with approximately 24 patients enrolled in order to achieve at least 18 evaluable patients. Additional patients may be dosed to ensure the minimum number of evaluable patients.
PK phase The PK phase is a non-randomised, open-label, 2-period design. Treatment Period 1 and Treatment Period 2 are separated by a 3 to 7 day washout period between doses. A study flow chart for the PK phase is presented in Figure 1. Patients will receive osimertinib 80 mg as a single dose on Day 1 of Treatment Period 2, then 80 mg once daily for 38 days (from Day 4 to Day 41 in Treatment Period 2). Patients will also receive a single oral dose of fexofenadine on Day 1 in Treatment Period 1, and on Days 1 and 39 in Treatment Period 2.
Continued access On completion of the PK phase (ie, following collection of the 72-hour fexofenadine sample on Day 42), patients may continue to take osimertinib tablets (80 mg once daily) as a single agent in continued access if they and the Investigator agree that this is appropriate. This will continue until the Investigator believes they are no longer deriving clinical benefit, or they stop taking osimertinib for any other reason. No clinical data will be collected during this phase other than sudden death of unknown reason, serious adverse events (SAEs) that may be related to osimertinib, outcomes of pregnancy and drug dispensing/accountability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, ≥18 years
- •Histological or cytological confirmation diagnosis of NSCLC
- •Radiological documentation of disease progression while receiving previous continuous treatment with an EGFR-TKI.
- •Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR-TKI sensitivity
- •ECOG performance status 0 to 1, with no deterioration over the previous 2 weeks.
- •Patients must have a life expectancy of 12 weeks or longer
- •Females should be using adequate contraceptive measures and must have a negative serum pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child bearing potential.
- •Male patients should be willing to use barrier contraception ie, condoms until 6 months after the last study drug is taken.
- •For inclusion in optional genetic research, patients must provide separate informed consent.
排除标准
- •Treatment with any of the following:
- •A 1st or 2nd generation EGFR-TKI within 8 days or approximately 5 half-lives, of the first dose of study treatment
- •Osimertinib in the present study [ie, dosing with osimertinib previously initiated in this study] or has previously received a 3rd generation EGFR-TKI [eg, CO 1686].
- •Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
- •Major surgery [excluding placement of vascular access] within 4 weeks of the first dose of study treatment.
- •Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment
- •Patients currently receiving [or unable to stop at least 3 weeks prior to first dose of osimertinib] medications or herbal supplements known to be potent inducers of CYP3A4 or inducers/inhibitors of P-gp.
- •Spinal cord compression or brain metastases, unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
- •Any of the following cardiac criteria:
- •Mean resting corrected QT interval corrected for heart rate using Fridericia's correction factor [QTcF] greater than 470 msec, obtained from 3 ECGs.
- •Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG [eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval greater than 250 msec]
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
- •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- •Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- •Absolute neutrophil count [ANC] less than 1.5 × 109/L
- •Platelet count less than 100 × 109/L
- •Haemoglobin less than 90 g/L
- •ALT greater than 2.5 times ULN if no demonstrable liver metastases or greater than 5 times ULN in the presence of liver metastases
- •AST greater than 2.5 times ULN if no demonstrable liver metastases or greater than 5 times ULN in the presence of liver metastases
- •Total bilirubin greater than 1.5 times ULN if no liver metastases or greater than 3 times ULN in the presence of liver metastases
- •Creatinine greater than 1.5 times institutional ULN concurrent with creatinine clearance less than 50 mL/min [measured or calculated by Cockcroft-Gault formula]
- •Patients unable to swallow orally administered medication or with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of the study drugs.
研究组 & 干预措施
osimertinib and fexofenadine
Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
干预措施: Fexofenadine tablet dosing (Drug)
osimertinib and fexofenadine
Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
干预措施: Osimertininb tablet dosing (Drug)
结局指标
主要结局
Fexofenadine Cmax (alone and in combination with osimertinib)
时间窗: Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2
To characterize the pharmacokinetics of fexofenadine by assessment of maximum plasma fexofenadine concentration.
Fexofenadine AUC (alone and in combination with osimertinib)
时间窗: Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2.
To characterize the pharmacokinetics of fexofenadine by assessment of area under the plasma concentration time curve from zero to infinity
次要结局
- Fexofenadine tmax (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Fexofenadine Vz/F (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) single dose: AUC0-72(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) single dose: Cmax(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 2)
- Fexofenadine CL/F (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Fexofenadine t½λz (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Fexofenadine AUC0-t (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Safety data collected using: Assessment of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0(Part A, approximately 11 weeks)
- Fexofenadine λz (alone and in combination with osimertinib)(Blood samples are collected pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 1 and Day 1 and Day 39 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) single dose: MRCmax(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: AUCtau(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Safety data collected using: laboratory parameters (clinical chemistry, heamatology, urinalysis)(Part A, approximately 11 weeks)
- Osimertinib and metabolites (AZ5104 and AZ7550)(Blood samples are collected pre-dose on D11, D18, D25, and D32)
- Osimertinib and metabolites (AZ5104 and AZ7550) single dose: tmax(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24, 36, 48, 60, 72 on Day 1 in Period 2)
- Safety data collected using: physical examination(Part A, approximately 11 weeks)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose Css,max(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: CLss/F (osimertinib only)(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Safety data collected using: Assessment of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)(Part A and Continuous Access, approximately 24 months)
- Safety data collected using: standard 12-lead electrocardiograms (ECGS)(Part A, approximately 11 weeks)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose Css,min(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple doses: MRAUCtau(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: MRCss,max(Blood samples are collected pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 24 on Day 39 in Period 2)
- Safety data collected using: vital signs (blood pressure, pulse, temperature, height, weight)(Part A, approximately 11 weeks)